Pharmacokinetics of Venetoclax, a Novel BCL‐2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non‐Hodgkin Lymphoma von Salem, Ahmed Hamed, Agarwal, Suresh K., Dunbar, Martin, Enschede, Sari L. Heitner, Humerickhouse, Rod A., Wong, Shekman L.

Volltext

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia von Roberts, Andrew W, Davids, Matthew S, Pagel, John M, Kahl, Brad S, Puvvada, Soham D, Gerecitano, John F, Kipps, Thomas J, Anderson, Mary Ann, Brown, Jennifer R, Gressick, Lori, Wong, Shekman, Dunbar, Martin, Zhu, Ming, Desai, Monali B, Cerri, Elisa, Heitner Enschede, Sari, Humerickhouse, Rod A, Wierda, William G, Seymour, John F

Volltext

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism von Anderson, Mary Ann, Deng, Jing, Seymour, John F., Tam, Constantine, Kim, Su Young, Fein, Joshua, Yu, Lijian, Brown, Jennifer R., Westerman, David, Si, Eric G., Majewski, Ian J., Segal, David, Heitner Enschede, Sari L., Huang, David C.S., Davids, Matthew S., Letai, Anthony, Roberts, Andrew W.

Volltext

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour act... von Wilson, Wyndham H, Prof, O'Connor, Owen A, Prof, Czuczman, Myron S, Prof, LaCasce, Ann S, MD, Gerecitano, John F, MD, Leonard, John P, Prof, Tulpule, Anil, MD, Dunleavy, Kieron, MD, Xiong, Hao, PhD, Chiu, Yi-Lin, PhD, Cui, Yue, PhD, Busman, Todd, MS, Elmore, Steven W, PhD, Rosenberg, Saul H, PhD, Krivoshik, Andrew P, MD, Enschede, Sari H, MD, Humerickhouse, Rod A, MD

Volltext

Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure–response analysis von Freise, Kevin J., Dunbar, Martin, Jones, Aksana K., Hoffman, David, Enschede, Sari L. Heitner, Wong, Shekman, Salem, Ahmed Hamed

Volltext

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease von ROBERTS, Andrew W, SEYMOUR, John F, YUE CUI, BUSMAN, Todd A, MCKEEGAN, Evelyn M, KRIVOSHIK, Andrew P, ENSCHEDE, Sari H, HUMERICKHOUSE, Rod, BROWN, Jennifer R, WIERDA, William G, KIPPS, Thomas J, SEONG LIN KHAW, CARNEY, Dennis A, HE, Simon Z, HUANG, David C. S, HAO XIONG

Volltext

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study von Stilgenbauer, Stephan, Prof, Eichhorst, Barbara, Prof, Schetelig, Johannes, Prof, Coutre, Steven, Prof, Seymour, John F, Prof, Munir, Talha, Prof, Puvvada, Soham D, MD, Wendtner, Clemens-Martin, Prof, Roberts, Andrew W, Prof, Jurczak, Wojciech, Prof, Mulligan, Stephen P, Prof, Böttcher, Sebastian, MD, Mobasher, Mehrdad, MD, Zhu, Ming, PhD, Desai, Monali, MD, Chyla, Brenda, PhD, Verdugo, Maria, MD, Enschede, Sari Heitner, MD, Cerri, Elisa, MD, Humerickhouse, Rod, MD, Gordon, Gary, MD, Hallek, Michael, Prof, Wierda, William G, MD

Volltext

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors von GANDHI, Leena, CAMIDGE, D. Ross, DIVE, Caroline, ENSCHEDE, Sari H, NOLAN, Cathy, CHIU, Yi-Lin, BUSMAN, Todd, HAO XIONG, KRIVOSHIK, Andrew P, HUMERICKHOUSE, Rod, SHAPIRO, Geoffrey I, RUDIN, Charles M, DE OLIVEIRA, Moacyr Ribeiro, BONOMI, Philip, GANDARA, David, KHAIRA, Divis, HANN, Christine L, MCKEEGAN, Evelyn M, LITVINOVICH, Elizabeth, HEMKEN, Philip M

Volltext

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents von Cheson, Bruce D., Heitner Enschede, Sari, Cerri, Elisa, Desai, Monali, Potluri, Jalaja, Lamanna, Nicole, Tam, Constantine

Volltext

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+... von Roberts, Andrew W., Advani, Ranjana H., Kahl, Brad S., Persky, Daniel, Sweetenham, John W., Carney, Dennis A., Yang, Jianning, Busman, Todd B., Enschede, Sari H., Humerickhouse, Roderick A., Seymour, John F.

Volltext

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM von Moreau, Philippe, Chanan-Khan, Asher, Roberts, Andrew W., Agarwal, Amit B., Facon, Thierry, Kumar, Shaji, Touzeau, Cyrille, Punnoose, Elizabeth A., Cordero, Jaclyn, Munasinghe, Wijith, Jia, Jia, Salem, Ahmed Hamed, Freise, Kevin J., Leverson, Joel D., Enschede, Sari Heitner, Ross, Jeremy A., Maciag, Paulo C., Verdugo, Maria, Harrison, Simon J.

Volltext

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma von Kumar, Shaji, Kaufman, Jonathan L., Gasparetto, Cristina, Mikhael, Joseph, Vij, Ravi, Pegourie, Brigitte, Benboubker, Lofti, Facon, Thierry, Amiot, Martine, Moreau, Philippe, Punnoose, Elizabeth A., Alzate, Stefanie, Dunbar, Martin, Xu, Tu, Agarwal, Suresh K., Enschede, Sari Heitner, Leverson, Joel D., Ross, Jeremy A., Maciag, Paulo C., Verdugo, Maria, Touzeau, Cyrille

Volltext

Analysis of Patient Characteristics and Treatment Progression Patterns in R/R DLBCL Patients Prior to CAR T-Cell Therapy in EU4+UK Countries von Heitner Enschede, Sari, Manuguid, Fil, Ricarte, Carolina, López Suárez, María, Jindal, Kriti, Mpima, Sheila

Volltext

Uptake of Novel Therapies into First-Line Treatment for AML Patients - EU5 Perspective von Moehler, Thomas, Ruiz, Magdalena, Casey, Vicky, Soares, Luana Margotto, Manuguid, Fil, Jindal, Kriti, Heitner Enschede, Sari

Volltext

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets von Souers, Andrew J, Leverson, Joel D, Boghaert, Erwin R, Ackler, Scott L, Catron, Nathaniel D, Chen, Jun, Dayton, Brian D, Ding, Hong, Enschede, Sari H, Fairbrother, Wayne J, Huang, David C S, Hymowitz, Sarah G, Jin, Sha, Khaw, Seong Lin, Kovar, Peter J, Lam, Lloyd T, Lee, Jackie, Maecker, Heather L, Marsh, Kennan C, Mason, Kylie D, Mitten, Michael J, Nimmer, Paul M, Oleksijew, Anatol, Park, Chang H, Park, Cheol-Min, Phillips, Darren C, Roberts, Andrew W, Sampath, Deepak, Seymour, John F, Smith, Morey L, Sullivan, Gerard M, Tahir, Stephen K, Tse, Chris, Wendt, Michael D, Xiao, Yu, Xue, John C, Zhang, Haichao, Humerickhouse, Rod A, Rosenberg, Saul H, Elmore, Steven W

Volltext

ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control von Seymour, John Francis, Davids, Matthew Steven, Pagel, John M., Kahl, Brad S., Wierda, William G., Puvvada, Soham, Gerecitano, John F., Kipps, Thomas J., Anderson, Mary Ann, Huang, David C.S., Rudersdorf, Nikita, Gressick, Lori A., Montalvo, Nicholas P., Yang, Jianning, Zhu, Ming, Dunbar, Martin, Cerri, Elisa, Enschede, Sari H., Humerickhouse, Rod, Roberts, Andrew Warwick

Volltext

Assessing the Role of BCOR/BCORL1 and Other Historically Low-Frequency Somatic Mutations in Myelodysplastic Syndromes von Alrifai, Taha, Edwin, Natasha, Bixby, Dale L., Hockenberry, Adam John, Okeke, Emmanuel, Mahon, Brett, Hassane, Duane C, Enschede, Sari Heitner, Larson, Melissa, Shammo, Jamile M.

Volltext

Profiling and treatment patterns in NSCLC patients with CNS (brain) metastases in Europe and Asia von Mari, Ettore, Mpima, Sheila, Guglielmetti, Filippo, Manuguid, Fil S., Enschede, Sari Heitner, Nasuti, Paola

Volltext

The impact of newly approved drugs on clinical and operational strategies for multiple myeloma clinical trials von Krishnan, Bhavani, Collins, Bernadette, Cho, Michael Jeffrey, Partridge, Tanya, Vighnay, Durga, Given, Marie, Enschede, Sari Heitner, Bochenska, Katarzyna, Hodge, Jeff Paul

Volltext

Biomarker and Ex Vivo Sensitivity Analysis of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma von Ross, Jeremy, Amiot, Martine, Chyla, Brenda, Roberts-Rapp, Lisa, Goswami, Rasna, Yan, Sun, Huang, Xin, Bhathena, Anahita, Enschede, Sari Heitner, Maciag, Paulo, Humerickhouse, Rod A., McKeegan, Evelyn

Volltext